Bristol-Myers Squibb, confirmation holds
Bristol-Myers Squibb gains 2.2% as the buy signal holds near its highs
Bristol-Myers Squibb, confirmation holds
Our view last week
Bristol-Myers Squibb rebounds 5.5% this week, a clean bounce off its daily 20-day moving average after a touch in the 57 area. Our model opens a fresh buy signal, but under the surface volumes are contracting and buyer dominance is fading: a case to handle with care, especially with earnings due in two weeks. The quality band flags this opening as high-risk.
This week's summary
Bristol-Myers Squibb shares close the confirmation week higher, +2.2%, with price still glued to its recent highs: a level already tested multiple times, where a straight breakout stays risky. Earnings land this very week, on July 30, and raise the stakes on every move. Our weekly technical analysis reads a solid but not-yet-broken setup, with volume and money flow staying lukewarm.
IQS Phase
74
in tension
Signal Strength
47
medium · weak
Sizing
REDUCED
Ranking
#74 / 124
US stocks in progress
Trade P&L %
+2.22%
from signal to today
Rank position
ranks 74th among the 124 Longs already running for US stocks in our ranking, with a signal strength of 47 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly +0.92% · monthly +6.01%
BMY belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content